Amgen Lung Cancer Study Shows Significant Survival Benefit in Phase 3 Trial

Key Facts

In a move that underscores the evolving landscape of immunotherapy, Amgen announced landmark Phase 3 results from its DeLLphi-305 study. The data revealed that IMDELLTRA, in combination with AstraZeneca’s Imfinzi, demonstrated a statistically significant improvement in overall survival for patients with extensive-stage small cell lung cancer (ES-SCLC). This marks the first time a Bispecific T-cell Engager (BiTE) therapy has shown a definitive survival benefit in this specific clinical setting, potentially establishing a new standard of care.

These clinical milestones are critical for mega-cap biotech firms as they seek to solidify long-term value through oncology breakthroughs. Per market data, AstraZeneca (AZN) shares stood at $162.7 at the close of September 4, 2026. The successful trial results for IMDELLTRA are expected to drive sentiment for Amgen, as the therapy targets a major indication with high unmet medical needs, according to analyst reports.

Investors are now looking toward regulatory milestones as the next primary catalysts for the sector. AZN closed at $162.7 (close September 4, 2026), maintaining a range between $161.13 and $163.78. With no immediate pharmaceutical-specific events in the upcoming economic calendar, market attention remains focused on the long-term commercial potential of this newly validated combination therapy.